α‐synuclein conformational antibodies fused to penetratin are effective in models of Lewy body disease

Progressive accumulation of α‐synuclein (α‐syn) has been associated with Parkinson's disease (PD) and Dementia with Lewy body (DLB). The mechanisms through which α‐syn leads to neurodegeneration are not completely clear; however, the formation of various oligomeric species have been proposed to play a role. Antibody therapy has shown effectiveness at reducing α‐syn accumulation in the central nervous system (CNS); however, most of these studies have been conducted utilizing antibodies that recognize both monomeric and higher molecular weight α‐syn. In this context, the main objective of this study was to investigate the efficacy of immunotherapy with single‐chain antibodies (scFVs) against specific conformational forms of α‐syn fused to a novel brain penetrating sequence.

• Publication year

  2016

• Venue

  Annals of Clinical and Translational Neurology

• Publication date

  2016-06-16

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1002/acn3.321PMID 27606342PMCID 4999592
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Oligomeric α‐synuclein and β‐amyloid variants as potential biomarkers for Parkinson's and Alzheimer's diseases

  2016cited by this paper
• Anti-Human α-Synuclein N-Terminal Peptide Antibody Protects against Dopaminergic Cell Death and Ameliorates Behavioral Deficits in an AAV-α-Synuclein Rat Model of Parkinson’s Disease

  2015cited by this paper
• Penetratin Story: An Overview.

  2015cited by this paper
• Region-Dependent Role of Cell-Penetrating Peptides in Insulin Absorption Across the Rat Small Intestinal Membrane

  2015cited by this paper
• Cell-Penetrating Peptides Selectively Cross the Blood-Brain Barrier In Vivo

  2015cited by this paper
• Application of CPPs for Brain Delivery.

  2015cited by this paper
• Toxic Oligomeric Alpha-Synuclein Variants Present in Human Parkinson’s Disease Brains Are Differentially Generated in Mammalian Cell Models

  2015cited by this paper
• Immunotherapeutic Approaches Targeting Amyloid-β, α-Synuclein, and Tau for the Treatment of Neurodegenerative Disorders

  2015cited by this paper
• A Sensitive phage‐based capture ELISA for sub‐femtomolar detection of protein variants directly from biological samples

  2015cited by this paper
• Generation and characterization of novel conformation-specific monoclonal antibodies for α-synuclein pathology.

  2015cited by this paper
• Active immunization against alpha-synuclein ameliorates the degenerative pathology and prevents demyelination in a model of multiple system atrophy

  2015cited by this paper
• ESCRT-mediated Uptake and Degradation of Brain-targeted α-synuclein Single Chain Antibody Attenuates Neuronal Degeneration In Vivo

  2014cited by this paper
• Reducing C-Terminal-Truncated Alpha-Synuclein by Immunotherapy Attenuates Neurodegeneration and Propagation in Parkinson's Disease-Like Models

  2014cited by this paper
• Annals of Clinical and Translational Neurology

  2014cited by this paper
• Next-generation active immunization approach for synucleinopathies: implications for Parkinson’s disease clinical trials

  2014cited by this paper
• Immunotherapy targeting α-synuclein protofibrils reduced pathology in (Thy-1)-h[A30P] α-synuclein mice.

  2014cited by this paper
• Accumulation of oligomer-prone α-synuclein exacerbates synaptic and neuronal degeneration in vivo.

  2014cited by this paper
• α-Synuclein Immunotherapy Blocks Uptake and Templated Propagation of Misfolded α-Synuclein and Neurodegeneration

  2014cited by this paper
• Hippocampal neuronal cells that accumulate α-synuclein fragments are more vulnerable to Aβ oligomer toxicity via mGluR5 – implications for dementia with Lewy bodies

  2014cited by this paper
• Lentivirus mediated delivery of neurosin promotes clearance of wild-type α-synuclein and reduces the pathology in an α-synuclein model of LBD.

  2013cited by this paper
• Alpha-synuclein Post-translational Modifications as Potential Biomarkers for Parkinson Disease and Other Synucleinopathies

  2013cited by this paper
• Functional genomics identifies five distinct molecular subtypes with clinical relevance and pathways for growth control in epithelial ovarian cancer

  2013cited by this paper
• Oxidative and nitrative alpha‐synuclein modifications and proteostatic stress: implications for disease mechanisms and interventions in synucleinopathies

  2013cited by this paper
• Caudo-rostral brain spreading of α-synuclein through vagal connections

  2013cited by this paper
• Immunotherapy for neurodegenerative diseases: focus on α-synucleinopathies.

  2013cited by this paper
• Axonopathy in an α-synuclein transgenic model of Lewy body disease is associated with extensive accumulation of C-terminal-truncated α-synuclein.

  2013cited by this paper
• TOM40 Mediates Mitochondrial Dysfunction Induced by α-Synuclein Accumulation in Parkinson’s Disease

  2013cited by this paper
• Transfer of human α-synuclein from the olfactory bulb to interconnected brain regions in mice

  2013cited by this paper
• scFv Antibody: Principles and Clinical Application

  2012cited by this paper
• Extracellular Alpha-Synuclein Oligomers Modulate Synaptic Transmission and Impair LTP Via NMDA-Receptor Activation

  2012cited by this paper
• Antibody-Aided Clearance of Extracellular α-Synuclein Prevents Cell-to-Cell Aggregate Transmission

  2012cited by this paper
• Prion-like acceleration of a synucleinopathy in a transgenic mouse model.

  2012cited by this paper
• Cognitive deficits in a mouse model of pre‐manifest Parkinson’s disease

  2012cited by this paper
• Recombinant Single-Chain Antibody with the Trojan Peptide Penetratin Positioned in the Linker Region Enables Cargo Transfer Across the Blood–Brain Barrier

  2012influential reference
• Penetratin story: an overview.

  2011cited by this paper
• In vivo demonstration that α-synuclein oligomers are toxic

  2011cited by this paper
• Passive Immunization Reduces Behavioral and Neuropathological Deficits in an Alpha-Synuclein Transgenic Model of Lewy Body Disease

  2011cited by this paper
• Alterations in mGluR5 Expression and Signaling in Lewy Body Disease and in Transgenic Models of Alpha-Synucleinopathy – Implications for Excitotoxicity

  2010influential reference
• Neurodegeneration in a Transgenic Mouse Model of Multiple System Atrophy Is Associated with Altered Expression of Oligodendroglial-Derived Neurotrophic Factors

  2010cited by this paper
• Genetic mouse models of Parkinson's disease The state of the art.

  2010cited by this paper
• Inclusion formation and neuronal cell death through neuron-to-neuron transmission of α-synuclein

  2009cited by this paper
• Intracellular targeting and clearance of oligomeric alpha-synuclein alleviates toxicity in mammalian cells.

  2009cited by this paper
• Beclin 1 Gene Transfer Activates Autophagy and Ameliorates the Neurodegenerative Pathology in α-Synuclein Models of Parkinson's and Lewy Body Diseases

  2009cited by this paper
• Mutant Pink1 induces mitochondrial dysfunction in a neuronal cell model of Parkinson’s disease by disturbing calcium flux

  2009cited by this paper
• Detecting Morphologically Distinct Oligomeric Forms of α-Synuclein*

  2009cited by this paper
• The adhesive removal test: a sensitive method to assess sensorimotor deficits in mice

  2009cited by this paper
• Formation of Toxic Oligomeric α-Synuclein Species in Living Cells

  2008cited by this paper
• An scFv intrabody against the nonamyloid component of alpha-synuclein reduces intracellular aggregation and toxicity.

  2008cited by this paper
• Mechanisms of Hybrid Oligomer Formation in the Pathogenesis of Combined Alzheimer's and Parkinson's Diseases

  2008cited by this paper
• Correction: Formation of Toxic Oligomeric α-Synuclein Species in Living Cells

  2008cited by this paper
• Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host-to-graft disease propagation

  2008cited by this paper
• Comprar The Mouse Brain in Stereotaxic Coordinates, The coronal plates and diagrams Compact, 3rd Edition | Keith Franklin | 9780123742445 | Academic Press

  2008cited by this paper
• Aggregated α-Synuclein Mediates Dopaminergic Neurotoxicity In Vivo

  2007cited by this paper
• Isolation of a human single chain antibody fragment against oligomeric alpha-synuclein that inhibits aggregation and prevents alpha-synuclein-induced toxicity.

  2007influential reference
• Different species of alpha-synuclein oligomers induce calcium influx and seeding.

  2007cited by this paper
• Physiological and pathological properties of alpha-synuclein.

  2007cited by this paper
• Physiological and pathological properties of α-synuclein

  2007cited by this paper
• Targeted delivery of proteins across the blood–brain barrier

  2007cited by this paper
• Different Species of α-Synuclein Oligomers Induce Calcium Influx and Seeding

  2007cited by this paper
• Isolation of a human single chain antibody fragment against oligomeric α-synuclein that inhibits aggregation and prevents α-synuclein induced toxicity

  2007cited by this paper
• Production and purification of lentiviral vectors

  2006cited by this paper
• Detection of oligomeric forms of α‐synuclein protein in human plasma as a potential biomarker for Parkinson's disease

  2006cited by this paper
• Behavioral effects of dopaminergic agonists in transgenic mice overexpressing human wildtype alpha-synuclein.

  2006cited by this paper
• Effects of alpha-synuclein immunization in a mouse model of Parkinson's disease.

  2005cited by this paper
• Effects of α-Synuclein Immunization in a Mouse Model of Parkinson’s Disease

  2005cited by this paper
• A human single-chain Fv intrabody blocks aberrant cellular effects of overexpressed α-synuclein

  2004cited by this paper
• The new mutation, E46K, of α‐synuclein causes parkinson and Lewy body dementia

  2004cited by this paper
• A human single-chain Fv intrabody blocks aberrant cellular effects of overexpressed alpha-synuclein.

  2004cited by this paper
• Neprilysin Gene Transfer Reduces Human Amyloid Pathology in Transgenic Mice

  2003cited by this paper
• Studies on the Internalization Mechanism of Cationic Cell-penetrating Peptides*

  2003cited by this paper
• The mouse brain in stereotaxic coordinates

  2003cited by this paper
• Differential neuropathological alterations in transgenic mice expressing α‐synuclein from the platelet‐derived growth factor and Thy‐1 promoters

  2002cited by this paper
• Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders.

  2000cited by this paper
• Widespread alterations of alpha-synuclein in multiple system atrophy.

  1999cited by this paper
• A short region of its homeodomain is necessary for engrailed nuclear export and secretion.

  1999cited by this paper
• Widespread Alterations of α-Synuclein in Multiple System Atrophy

  1999cited by this paper
• Glial cytoplasmic inclusions in white matter oligodendrocytes of multiple system atrophy brains contain insoluble α‐synuclein

  1998cited by this paper
• Aggregation of alpha-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies.

  1998cited by this paper
• Filamentous alpha-synuclein inclusions link multiple system atrophy with Parkinson's disease and dementia with Lewy bodies.

  1998cited by this paper
• α-Synuclein immunoreactivity in glial cytoplasmic inclusions in multiple system atrophy

  1998cited by this paper
• Filamentous α-synuclein inclusions link multiple system atrophy with Parkinson's disease and dementia with Lewy bodies

  1998cited by this paper
• Alpha-synuclein immunoreactivity in glial cytoplasmic inclusions in multiple system atrophy.

  1998cited by this paper
• The third helix of the Antennapedia homeodomain translocates through biological membranes.

  1994cited by this paper
• Isolation of complementary DNA clones encoding the human lymphocyte glycoprotein T1/Leu-1

  1986cited by this paper

• A bibliometric analysis of alpha-synuclein in Parkinson’s disease from 2015 to 2024

  2026cites this paper
• Unraveling synucleinopathies: Recent breakthroughs in Parkinson's disease therapy.

  2025cites this paper
• ENGINEERED NANOBODIES WITH PROGRAMMABLE TARGET ANTIGEN PROTEOLYSIS (PTAP) FUSIONS REGULATE INTRACELLULAR ALPHA-SYNUCLEIN IN VITRO AND IN VIVO

  2024cites this paper
• α-Synuclein pathology as a target in neurodegenerative diseases

  2024cites this paper
• The humoral immune landscape in Parkinson's disease: Unraveling antibody and B cell changes

  2024cites this paper
• Targeting cerebral diseases with enhanced delivery of therapeutic proteins across the blood-brain barrier

  2023cites this paper
• Inhibition of Protein Aggregation and Endoplasmic Reticulum Stress as a Targeted Therapy for α-Synucleinopathy

  2023cites this paper
• A Mouse Model to Test Novel Therapeutics for Parkinson’s Disease: an Update on the Thy1-aSyn (“line 61”) Mice

  2023cites this paper
• Effects of oligomer toxicity, fibril toxicity and fibril spreading in synucleinopathies

  2022cites this paper
• Applications of nanobodies in brain diseases

  2022cites this paper
• Reduction of αSYN Pathology in a Mouse Model of PD Using a Brain-Penetrating Bispecific Antibody

  2022cites this paper
• Targeting alpha-synuclein or tau for treating neurodegenerative movement disorders.

  2022cites this paper
• Therapeutics in the Pipeline Targeting α-Synuclein for Parkinson's Disease

  2022cites this paper
• Transportation of Single-Domain Antibodies through the Blood–Brain Barrier

  2021cites this paper
• Exploring the Release of Toxic Oligomers from α-Synuclein Fibrils with Antibodies and STED Microscopy

  2021cites this paper
• Fibrillar form of α-synuclein-specific scFv antibody inhibits α-synuclein seeds induced aggregation and toxicity

  2020cites this paper
• Synucleinopathies: Where we are and where we need to go

  2020cites this paper
• Immunotherapies for Aging-Related Neurodegenerative Diseases—Emerging Perspectives and New Targets

  2020cites this paper
• Engineered Extracellular Vesicles/Exosomes as a New Tool against Neurodegenerative Diseases

  2020cites this paper
• Antibody Fragments as Tools for Elucidating Structure-Toxicity Relationships and for Diagnostic/Therapeutic Targeting of Neurotoxic Amyloid Oligomers

  2020cites this paper
• Virus-mediated delivery of antibody targeting TAR DNA-binding protein-43 mitigates associated neuropathology

  2019cites this paper
• Therapeutic Potential of CPPs

  2019cites this paper
• α-Synuclein pathology in Parkinson's disease and related α-synucleinopathies.

  2019cites this paper
• Targeting Strategies

  2019cites this paper
• Characterization of novel conformation-selective α-synuclein antibodies as potential immunotherapeutic agents for Parkinson's disease.

  2019cites this paper
• Systemic peptide mediated delivery of an siRNA targeting α-syn in the CNS ameliorates the neurodegenerative process in a transgenic model of Lewy body disease.

  2019influential citation
• Selective targeting of 3 repeat Tau with brain penetrating single chain antibodies for the treatment of neurodegenerative disorders

  2018cites this paper
• Immune system responses in Parkinson's disease: Early and dynamic

  2018cites this paper
• Immunotherapy targeting toll-like receptor 2 alleviates neurodegeneration in models of synucleinopathy by modulating α-synuclein transmission and neuroinflammation

  2018cites this paper
• Safety and Tolerability of Multiple Ascending Doses of PRX002/RG7935, an Anti–&agr;-Synuclein Monoclonal Antibody, in Patients With Parkinson Disease: A Randomized Clinical Trial

  2018cites this paper
• Targeting Malignant Brain Tumors with Antibodies

  2017cites this paper
• Differential effects of immunotherapy with antibodies targeting α-synuclein oligomers and fibrils in a transgenic model of synucleinopathy.

  2017cites this paper
• Targeting α‐Synuclein as a therapy for Parkinson's disease: The battle begins

  2017cites this paper
• Preclinical development of a vaccine against oligomeric alpha-synuclein based on virus-like particles

  2017cites this paper
• Recent advances in treating Parkinson’s disease

  2017cites this paper
• TDP-43 protein variants as biomarkers in amyotrophic lateral sclerosis

  2017cites this paper
• Alpha-synuclein oligomers: a new hope

  2017cites this paper
• Alpha-Synuclein Oligomers—Neurotoxic Molecules in Parkinson's Disease and Other Lewy Body Disorders

  2016cites this paper